News

Blow for Novo’s insulin Tresiba
Enlarge image

RegulatoryDenmarkEUFrance

Blow for Novo’s insulin Tresiba

08.11.2012 - Novo Nordisk’s shares dropped after the FDA said that its long-acting insulin degludec had heart safety risks prior to a meeting of agency advisers.

With the ultra-long acting insulin analogon Tresiba (insulin degludec) filed for market authorisation, the Danish drugmaker wanted to take a piece of the cake of Sanofi’s bestseller Lantus, which made €3.9bn in sales last year. But after the US Food and Drug Administration (FDA) released a report questioning whether more safety studies should be conducted, analysts had doubts over Novo’s plans. “We see the risk of a significant delay to the U.S. approval as being substantially higher than before,” stated Jeffrey Holford, an analyst at Jefferies & Co. in New York. and downgraded the stock to "hold" from "buy". Prior to the news, Tresiba, which must be only taken once daily, was expected to make €1.1bn annually. After it shares dropped by almost 7%, the lowest value since last August.

In the FDA staff document, the cardiovascular risk of degludec is higher than previously published reports. However it is not clear if the FDA advisors will recommend them to conduct additional studies pre- or post-approval.  According to analyst Martin Voegtli from Zurich-based Kepler Capital Markets, the most probable scenario is market authorisation in early 2013 with the obligation to conduct post-marketing studies to investigate the cardiovascular risk of degludec.

In summer, Novo claimed Tresiba to have a benefit over Sanofi’s Lantus in reduction of hypoglycemia but analysts seem sceptic. Tresiba has already gained market authorisation in Japan and was recommended for market approval by the EU CHMP in mid-October. Morgan Stanley analysts Peter Verdult and Chris Eccles said in mid-October that the see a 3% annual growth of Lantus in the €12bn diabetes market even after expiry of the patent in 2015 and competition by degludec. With Lantus Sanofi makes 20% of its profits. The analysts value Sanofi’s value at „overweight“.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/blow-for-novos-insulin-tresiba.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.10 CHF7.84%
  • WILEX3.40 EUR6.25%
  • 4SC1.28 EUR4.07%

FLOP

  • BIOFRONTERA2.36 EUR-6.35%
  • FORMYCON29.79 EUR-6.35%
  • STRATEC BIOMEDICAL47.35 EUR-5.66%

TOP

  • 4SC1.28 EUR52.4%
  • VITA 346.59 EUR18.7%
  • CO.DON3.11 EUR17.8%

FLOP

  • MOLOGEN5.10 EUR-35.4%
  • CYTOS1.10 CHF-28.6%
  • BIOFRONTERA2.36 EUR-10.9%

TOP

  • SANTHERA100.80 CHF2511.4%
  • CYTOS1.10 CHF746.2%
  • FORMYCON29.79 EUR328.6%

FLOP

  • MOLOGEN5.10 EUR-54.5%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.36 EUR-29.6%

No liability assumed, Date: 24.04.2015